anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Idiopathic pulmonary fibrosis (IPF) carries a high mortality rate and has a poor prognosis. The pathogenesis of pulmonary fibrosis (PF) is highly related to dysregulation of multiple RNAs. This study aims to identify and validate dysregulated RNAs that exhibited dynamic alterations in response to bleomycin (BLM)-induced PF. The results will provide therapeutic targets for patients suffering from IPF. Whole transcriptomic profiles of BLM-induced PF were obtained through high-throughput RNA sequencing. miRNA profiling was downloaded from GSE45789 database in the Gene Expression Omnibus (GEO). We identified the differentially expressed RNAs (DERNAs) that exhibited dynamic alterations in response to BLM-induced PF. Subsequently, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genome (KEGG) pathway enrichment analysis were conducted to discovery regulatory processes of PF. Weighted gene co-expression network analysis (WGCNA), protein-protein interaction (PPI) analysis, and co-expression analysis were performed to identify key genes and pathogenic pattern during the progression of PF. MiRanda, miRcode, and TargetScan were utilized to predict target relationships in the potential competing endogenous RNA (ceRNA) network. The results were verified by qRT-PCR analysis. In the context of BLM-induced PF, this study identified a total of 167 differentially expressed messenger RNAs (DEmRNAs), 115 differentially expressed long non-coding RNAs (DElncRNAs), 45 differentially expressed circular RNAs (DEcircRNAs), and 87 differentially expressed microRNAs (DEmiRNAs). These RNA molecules showed dynamic alterations in response to BLM-induced PF. These DEmRNAs exhibited a predominant association with the biological processes pertaining to the organization of extracellular matrix. A regulatory network was built in PF, encompassing 31 DEmRNAs, 18 DE lncRNAs, 13 DEcircRNAs, and 13 DEmiRNAs. Several DERNA molecules were subjected to validate using additional BLM-induced PF model. The outcomes of this validation process shown a strong correlation with the results obtained from RNA sequencing analysis. The GSE213001 dataset was utilized to validate the expression levels and diagnostic efficacy of four specific hub mRNAs (CCDC80, CLU, COL5A1, and COL6A3) in individuals diagnosed with PF. In this study, we identified and validated several RNA molecules that exhibited dynamic alternations in response to BLM-induced PF. These dysregulated RNAs participated in the pathogenesis of PF and can be used as therapeutic targets for early-stage IPF. Although more work must be done to confirm the results, our study may provide directions for future studies.
The invention discloses a traditional Chinese medicine composition for treating common cold with the syndrome of wind-cold fettering the exterior and a preparation method thereof. The traditional Chinese medicine composition is characterized by being prepared from the following medicinal materials, by weight, 10-30 parts of Clausena excavata Burm. f., 9-21 parts of Primula sieboldii E. Morren, 2-14 parts of biden bipinnata, 6-18 parts of Chrysopogon aciculatus (Retz.)Trin, 10-30 parts of blue gum, 9-21 parts of common bluebeard herb, 9-21 parts of Crepis phoenix Dunn, 10-30 parts of paulownia flower, 4-16 parts of marigold, 15-35 parts of Wu huan shu qiang, 6-18 parts of Schefflera rubriflora Tseng et Hoo, 2-14 parts of Aglaia odorata Lour., 6-18 parts of Artemisia dracunculus L., 30-70 parts of Kyllinga monocephala Rottb and 2-14 parts of liquorice. The traditional Chinese medicine composition provided by the invention has advantages of high efficiency and reliable curative effect. By the use of the traditional Chinese medicine composition, relapse of common cold with syndrome of wind-cold fettering the exterior will be avoided after recovery.
This group will not undergo the physical exercise intervention but will receive general recommendations for comprehensive health care. These include information about the benefits of physical exercise and tips for managing physical and mental health. The control group (CG) will undergo all the proposed physical and mental tests at the beginning of the study and again after 12 weeks. Additionally, during the study period, they will be monitored for changes in physical activity levels, as well as nutritional changes, sleep habits, and stress levels.
FIELD: medicine. SUBSTANCE: method involves treating patients in two stages. The first stage begins with taking saline purgative followed by rectal introduction of purgative decoction of medical herbs species. Vegetable salt-free diet and medical herbs species decoction rich in vitamins twice a day are administered. Rectal introduction of tranquilizing decoction of medical herbs species is administered at the beginning of the second day, food uptake is ruled out, apple juice is used as liquid for drinking. Olive oil and lemon juice are taken at the end of the day at prescribed quantity 4-5 times a day each 15 min with hot water bag applied to the region of liver followed with medical herbs species decoction rich in vitamins to be taken. During the third and the fourth day, rectal introduction of cholagogue and tonic decoctions of medical herbs species are administered in two procedures, respectively. Medical herbs species decoctions rich in vitamins are taken in the morning time. Vegetable salt-free diet and kefir prepared on the basis of a medical prophylactic preparation are taken at the third, fourth and fifth day. The second stage begins not later than at the thirties day from the moment the first stage is over. Food uptake is ruled out and citrus juices mixture is taken for drinking during 4 days at the second stage. Rectal introduction of tranquilizing, cholagogue and tonic decoctions of medical herbs species are administered twice a day at the first, second, third and fourth days, respectively. Enterosorbent and kefir prepared on the basis of a medical prophylactic preparation are administered beginning with the third day. Vegetable salt-free diet is administered at the last fifth day. Vegetable diet with vegetable and fruits relief days included as well as vegetable juice therapy and phytotherapy are prescribed after two stages of the treatment are over. Purgative herbs species has Rhamnus alnus L. bark, fennel, licorice bitter (root), tansy, senna leaves. Tranquilizing herbs species has vandal root, motherwort (herb), medical matricary, sweetbrier (herb), raspberry (leaves). Cholagogue herbs species has pepper mint, vandal root, Helichrysum arenarium L., milfoil, coriander (fruits), calendula (herb). Tonic herbs species has echinopanax (root), pink radiola, dioecious nettle (herb), calendula (flowers). Infusion of mixed medical herbs including haricot in pods, bilberry (leaves), camomile (flowers), Equisetum arvense L. , sweetbrier, Hypericum L. is applied. EFFECT: enhanced effectiveness of treatment. 7 cl
Upon confirming the diagnosis of pregnancy, women should immediately inform the doctor. 

Metoprolol has been shown to increase postimplantation loss and decrease neonatal survival in rats at doses up to 11 times the maximum daily human dose of 450 mg, when based on surface area. Distribution studies in mice confirm exposure of the fetus when metoprolol is administered to the pregnant animal. These limited animal studies do not indicate direct or indirect harmful effects with respect to teratogenicity (see Carcinogenesis, Mutagenesis, Impairment of Fertility). 

There are no adequate and well-controlled studies in pregnant women. The amount of data on the use of metoprolol in pregnant women is limited. The risk to the fetus/mother is unknown. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
INTRODUCTION: X-linked dystonia-parkinsonism (XDP) is a progressive neurodegenerative disorder that has been studied well in recent years.
OBJECTIVES: This scoping review aimed to describe the current state of knowledge about the diagnosis and treatment of XDP, to provide clinicians with a concise and up-to-date overview.
METHODS: We conducted a scoping review of pertinent literature on the diagnosis and treatment of XDP using Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews guidelines.
RESULTS: There were 24 articles on diagnostic methods and 20 articles on therapeutic interventions for XDP, with 7 review articles describing both. The detection of the SVA retrotransposon insertion within the TAF1 gene is confirmatory for XDP. Oral medications are marginally effective. Chemodenervation with botulinum toxin is an effective treatment. Pallidal deep brain stimulation (DBS) has been shown to provide significant improvement in the dystonia and quality of life of patients with XDP for a longer time. A less invasive surgical option is the transcranial magnetic resonance-guided focused ultrasound (tcMRgFUS), which has shown promising effects with the limited number of case reports available.
CONCLUSION: XDP is a geneti disorder characterized by striatal symptoms and pathology on neuroimaging. No effective oral medications are available for the management of XDP. The use of botulinum toxin is limited by its cost and duration of effects. As of now, pallidal DBS is deemed to be the best option. Another promising option is the tcMRgFUS but still has limited studies on its safety and efficacy in XDP.
BACKGROUND: A common cause of mild thrombocytopenia is chronic liver disease, the most common etiology being metabolic dysfunction-associated steatotic liver disease (MASLD). Mild thrombocytopenia is a well-defined, independent marker of hepatic fibrosis in patients with chronic liver disease. Currently, there is a paucity of information available to characterize perioperative risk in patients with MASLD; therefore, the characterization of perioperative morbidity is paramount. We used a platelet threshold of 150×10 9 as a surrogate for fibrosis in patients undergoing laparoscopic cholecystectomy to study its effect on perioperative complications and mortality.
PATIENTS AND METHODS: We queried the American College of Surgeons National Surgical Quality Improvement Program database for laparoscopic cholecystectomies occurring from 2005 through 2018. Demographic differences between patients with and without thrombocytopenia were evaluated using the t test or the χ 2 test, whereas adjusted and unadjusted differences in outcome risk were evaluated using log-binomial regression models.
RESULTS: We identified 437,630 laparoscopic cholecystectomies of which 6.9% included patients with thrombocytopenia. Patients with thrombocytopenia were more often males, older, and with chronic disease. Patients with thrombocytopenia and higher Aspartate Aminotransferase to Platelet Ratio Index scores had 30-day mortality rates risk ratio of 5.3 (95% CI: 4.8-5.9), with higher complication rates risk ratio of 2.4 (95% CI: 2.3-2.5). The most frequent complications included the need for transfusion, renal, respiratory, and cardiac.
CONCLUSIONS: Perioperatively, patients with mild thrombocytopenia undergoing laparoscopic cholecystectomy had higher mortality rates and complications compared with patients with normal platelet counts. Thrombocytopenia may be a promising, cost-effective tool to identify patients with MASLD and estimate perioperative risk, especially if used in high-risk populations.
Provided herein are methods of detecting or inhibiting melanoma growth based on Gab2 protein expression. Gab2 protein was found to be either amplified and/or overexpressed in melanoma. Gab2 protein expression correlated with clinical melanoma progression and higher levels of expression were seen in metastatic melanomas compared to primary melanoma and melanocytic nevi. Over-expression of Gab2 potentiates, whereas silencing of Gab2 reduces, migration and invasion of melanoma cells. Gab2 mediated hyperactivation of Akt signaling in the absence of growth factors and inhibition of the PI3K-Akt pathway decreased Gab2-mediated tumor cell migration and invasive potential. Gab2 over-expression resulted in enhanced tumor growth and metastatic potential in vivo. These results demonstrate a previously undefined role for Gab2 in melanoma tumor progression and metastasis.
In this comparative cross-linguistic study we test whether expressive interjections (words like ouch or yay) share similar vowel signatures across the world's languages, and whether these can be traced back to nonlinguistic vocalizations (like screams and cries) expressing the same emotions of pain, disgust, and joy. We analyze vowels in interjections from dictionaries of 131 languages (over 600 tokens) and compare these with nearly 500 vowels based on formant frequency measures from voice recordings of volitional nonlinguistic vocalizations. We show that across the globe, pain interjections feature a-like vowels and wide falling diphthongs ("ai" as in Ayyy! "aw" as in Ouch!), whereas disgust and joy interjections do not show robust vowel regularities that extend geographically. In nonlinguistic vocalizations, all emotions yield distinct vowel signatures: pain prompts open vowels such as [a], disgust schwa-like central vowels, and joy front vowels such as [i]. Our results show that pain is the only affective experience tested with a clear, robust vowel signature that is preserved between nonlinguistic vocalizations and interjections across languages. These results offer empirical evidence for iconicity in some expressive interjections. We consider potential mechanisms and origins, from evolutionary pressures and sound symbolism to colexification, proposing testable hypotheses for future research.
A method of modulating immunity in a mammal is provided by modulating Galectin-9 activity in the mammal. Promoting or enhancing immunity may be effected by activating or stimulating Galectin-9 activity in the mammal, such as by administering a Galectin-9 agonist to the mammal. The agonist may be multimeric, soluble PD-L2 or an agonist antibody that binds Galectin-9. Suppressing or preventing immunity may be achieved by inhibiting or blocking Galectin-9 activity in the mammal, such as by administering an antagonist antibody or antibody fragment that binds Galectin-9 or that prevents or inhibits PD-L2 multimerisation and/or binding to Galectin-9. The aforementioned methods may be suitable for preventing or treating a disease, disorder or condition responsive to modulation of Galectin-9 activity. Also provided is a method of designing, screening, engineering or otherwise producing a Galectin-9 agonist, inhibitor or antagonist that may be useful for modulating immunity by modulating Galectin-9 activity.
In Part 1 of the study, participants will receive a dose of 89Zr-GSK2849330 (Dose 1), with an activity of no more than 37 MegaBequerel (MBq) and a variable total dose of GSK2849330. PET scans will be acquired within 7 days. Two weeks after Dose 1 participants will receive second dose of 89Zr-GSK2849330 (Dose 2) and a variable total dose of GSK2849330. Participants will continue to receive unlabelled GSK2849330 (in Part 2) either at established dose level or as decided by medical monitor.
The conditioning regimen will be 200 mg/kg of intravenous cyclophosphamide given in 4 equal fractions on days -5 through -2 with intravenous mesna. Rabbit antithymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5, 1.0 mg/kg on days -4 and -3, and then 1.5 mg/kg on days -2 and -1. Methylprednisolone 1000 mg will be infused intravenously before each dose of rATG. Autologous hematopoietic stem cells will be infused intravenously on day 0. A granulocyte-colony stimulating factor (G-CSF) 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment. Intravenous Rituxan (500mg) will be administered on days -6 and +1.
BACKGROUND: Muscle aging is associated with a consistent decrease in the ability of muscle tissue to regenerate following intrinsic muscle degradation, injury or overuse. Age-related imbalance of protein synthesis and degradation, mainly regulated by AKT/mTOR pathway, leads to progressive loss of muscle mass. Maintenance of anabolic and regenerative capacities of skeletal muscles may be regarded as a therapeutic option for sarcopenia and other muscle wasting diseases. Our previous studies have demonstrated that BIO101, a pharmaceutical grade 20-hydroxyecdysone, increases protein synthesis through the activation of MAS receptor involved in the protective arm of renin-angiotensin-aldosterone system. The purpose of the present study was to assess the anabolic and pro-differentiating properties of BIO101 on C2C12 muscle cells in vitro and to investigate its effects on adult and old mice models in vivo.
METHODS: The effects of BIO101 on C2C12 differentiation were assessed using myogenic transcription factors and protein expression of major kinases of AKT/mTOR pathway by Western blot. The in vivo effects of BIO101 have been investigated in BIO101 orally-treated (50 mg/kg/day) adult mice (3 months) for 28 days. To demonstrate potential beneficial effect of BIO101 treatment in a sarcopenic mouse model, we use orally treated 22-month-old C57Bl6/J mice, for 14 weeks with vehicle or BIO101. Mice body and muscle weight were recorded. Physical performances were assessed using running capacity and muscle contractility tests.
RESULTS: Anabolic properties of BIO101 were confirmed by the rapid activation of AKT/mTOR, leading to an increase of C2C12 myotubes diameters (+26%, P < 0.001). Pro-differentiating effects of BIO101 on C2C12 myoblasts were revealed by increased expression of muscle-specific differentiation transcription factors (MyoD, myogenin), resulting in increased fusion index and number of nuclei per myotube (+39% and +53%, respectively, at day 6). These effects of BIO101 were like those of angiotensin (1-7) and were abolished with the use of A779, a MAS receptor specific antagonist. Chronic BIO101 oral treatment induced AKT/mTOR activation and anabolic effects accompanied with improved physical performances in adult and old animals (maximal running distance and maximal running velocity).
CONCLUSIONS: Our data suggest beneficial anabolic and pro-differentiating effects of BIO101 rendering BIO101 a potent drug candidate for treating sarcopenia and possibly other muscle wasting disorders.
Cervical myelopathy is a common condition due to degeneration of the cervical spine causing stenosis and cord compression, with a higher prevalence in Asian population. It leads to decreased hand dexterity and function, sensory loss, gait and sphincter disturbance. Natural history shows a stepwise deterioration in most cases, whilst a slow progressive deterioration or sudden deterioration is observed in small number of subjects.

The myelopathy hand was first described by Ono et al. on the analysis of finger motion impairment caused by cervical myelopathy. They described a 10 second grip and release test, which documents the number of times a subject can make a fist and release it as rapidly as possible within 10 seconds. The clumsiness associated with intrinsic finger weakness decreases the number of cycles a patient can perform during the test. They quantified patients' neurologic deficit and found that \<20 grip -release cycles in 10 seconds represented symptomatic myelopathy. The presence of this sign is not only pathognomonic of cervical myelopathy but also correlates with disease severity. This is a sensitive and specific sign of pyramidal tract involvement and has since become a classical sign and objective test of the condition. The presence of myelopathic hand signs aids the diagnosis of symptomatic cervical myelopathy and its grading acts a guide to the severity of the condition to the treating surgeon.

However, this quantitative analysis only provides a crude representation of the clumsiness that patients experience from their deterioration of hand function. In the original description, Ono et al. noted the quality of this movement was affected particularly in advanced cases, where there was difficult, slow and incomplete finger extension, exaggerated wrist flexion with attempted finger extension and exaggerated wrist extension with finger flexion. This was considered to be caused by a failure of synergy between the wrist and the fingers. Finger motion is complex, varies greatly and clinical evaluation is often difficult. Apart from the counting the number of cycles a patient can perform, the classical grip and release test contains other critical clinical information that has been widely described by surgeons but in very vague terms that are neither reproducible nor meaningful in clinical practice. Although this uncoordinated finger motion and inability to move their fingers smoothly in grip and release cycles are well-known phenomena in myelopathy patients, they have been only vaguely recognized. Presently these kinematic characteristics have not been quantified or studied, and it is not known which types of myelopathy present with them, how it correlates with disease severity and its prognosticating value.
Traumatic iliac arteriovenous fistula is a rare complication of vascular injury. Open surgical repair has an incidence of postoperative complications. In recent years, endovascular treatment has shown better efficacy. We report a 62-year-old female AVF patient with a stab injury history of more than 16 years. Computed tomography angiography (CTA) revealed a large arteriovenous fistula between the right internal iliac artery and the common iliac vein. After considering the patient's relevant conditions, an endovascular approach was satisfactorily performed with the implantation of an Amplatzer Vascular Plug II to interrupt the abnormal vascular communication and maintain arterial and venous patency. The final control images showed closure of the arteriovenous communication.
TQB2618 injection combined with Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin, 21 days as a treatment cycle. After 4\~6 cycles, TQB2618 injection combined with Penpulimab injection, 21 days as a treatment cycle.
The invention discloses a medicament for treating tumors. The medicament consists of a histone deacetylase inhibitor and a lysophosphatidic acid suppressant, wherein the lysophosphatidic acid suppressant is a substance for inhibiting lysophosphatidic acid from bonding with a lysophosphatidic acid receptor or a substance for inhibiting the lysophosphatidic acid from generating. The medicament indicates that the histone deacetylase inhibitor (HDACi) can up-regulate autotaxin (ATX) expression by inhibiting the activity of HDAC3 and HDAC7 in multiple tumor cells. The ATX generated by the induction of the HDACi generates the lysophosphatidic acid (LPA) by catalyzing lysophosphatidyl choline (LPC) and weakens the killing effect of the HDACi on the tumor cells. If the ATX expression is inhibited by a ribonucleic acid interference (RNAi) method or bromophosphonate-lysophosphatidic acid (BrP-LPA) serving as an ATX-LPA signal channel inhibitor is added to block an ATX-LPA signal, the killing effect of the HDACi on the tumor cells can be enhanced further. The study of the invention provides a new concept for treating the tumors by combing the lysophosphatidic acid suppressant and the HDACi. The medicament has wide application prospects in the treatment of the tumors.